International Index of Erectile Function questionnaire 31 · patients with erectile dysfunction in patients with multiple sclerosis
1 finding from 1 review
International Index of Erectile Function ‐ not reported · patients with erectile dysfunction in patients with multiple sclerosis
1 finding from 1 review
Sexual Encounter Profile questions 2 · patients with erectile dysfunction in patients with multiple sclerosis
Sildenafil showed no clear difference in sexual Encounter Profile questions 2 compared with placebo (low certainty).
1 finding from 1 review
Sexual Encounter Profile questions 3 · patients with erectile dysfunction in patients with multiple sclerosis
Sildenafil showed no clear difference in sexual Encounter Profile questions 3 compared with placebo (low certainty).
1 finding from 1 review
Global Assessment Question · patients with erectile dysfunction in patients with multiple sclerosis
Sildenafil probably leads to higher global Assessment Question compared with placebo (moderate certainty).
1 finding from 1 review
Relapse · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with relapses at 12 months Number of… compared with beta interferon (very low certainty).
2 findings from 1 review
Number of participants with progression at 12 months3 ‐ not reported · Multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants with progression at 24 months Number of participants with progression at 24 months · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with progression at 24 months Number of… compared with beta interferon (very low certainty).
1 finding from 1 review
Number of participants with new T2 or GELs at 12 months Number of participants with new T2 or GELs at 12 months · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with new T2 or GELs at 12 months Number of… compared with beta interferon (very low certainty).
1 finding from 1 review
Number of participants with new T2 or GELs at 24 months3 ‐ not reported · Multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Change in disability Assessed by: EDSS · Multiple sclerosis
1 finding from 1 review
Patients who progressed ‐ at 2 years · people with multiple sclerosis
Glatiramer acetate showed no clear difference in patients who progressed ‐ at 2 years compared with placebo; GRADE not reported.
2 findings from 1 review
Change in disability score at the end of · people with multiple sclerosis
2 findings from 1 review
Relapse · people with multiple sclerosis
1 finding from 1 review
Mean number of relapses ‐ at 2 years of · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Patients with progression of the disease ( · patients with Primary Progressive Multiple Sclerosis
The intervention showed no clear difference in patients with progression of the disease ( (high certainty).
1 finding from 1 review
Intervention not reported
Patients with severe adverse event ( · patients with Primary Progressive Multiple Sclerosis
The intervention showed no clear difference in patients with severe adverse event ( (high certainty).
1 finding from 1 review
Intervention not reported
Patients with any related adverse event ( · patients with Primary Progressive Multiple Sclerosis
The intervention leads to higher patients with any related adverse event ( (high certainty).
1 finding from 1 review
Intervention not reported
Mean EDSS change at two years ( · patients with Primary Progressive Multiple Sclerosis
1 finding from 1 review
Intervention not reported
Sustained increase in spasticity ( · patients with Primary Progressive Multiple Sclerosis
The intervention showed no clear difference in sustained increase in spasticity ( (high certainty).
1 finding from 1 review